Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 5240: Novel CD3-Fusion Receptor enables combination of T-cell engagers and allogeneic CAR T cells to promote enhanced antitumor activity and overcome antigen escape

View Full Paper
Ask AI
Bookmark
Share

Authors

DLDan LuEPEigen PeraltaHCHui-Yi Chu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lu et al. (2024) studied this question.

synapsesocial.com/papers/68e72e24b6db6435876a77abhttps://doi.org/10.1158/1538-7445.am2024-5240
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 7147: CAR T-Cell therapy efficacy evaluation inTumorGraft3D tri-culture platform with reconstructed tumor microenvironment2026
  2. 2Abstract LB068: Repurposing chimeric antigen receptor regulatory T cells for treating cancer2024
  3. 3Abstract 1612: Novel CD3 binders enable T cell engagers with potent tumor control, limited cytokine release, and safe pairing with co-stimulation2026
  4. 4Abstract 3618: High-avidity BCMA CAR and high-affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma2024 · 1 citations
  5. 5Abstract 4278: Regulatory T cell inspired engineering of CAR-T cells enhances anti-tumor efficacy in solid tumors2026